255 related articles for article (PubMed ID: 19485909)
1. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.
Cugno M; Ingegnoli F; Gualtierotti R; Fantini F
Curr Vasc Pharmacol; 2010 Mar; 8(2):285-92. PubMed ID: 19485909
[TBL] [Abstract][Full Text] [Related]
2. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
Dixon WG; Symmons DP
Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
[TBL] [Abstract][Full Text] [Related]
3. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.
Chighizola C; Schioppo T; Ingegnoli F; Meroni PL
Curr Vasc Pharmacol; 2012 Sep; 10(5):639-46. PubMed ID: 22272912
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
6. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
[TBL] [Abstract][Full Text] [Related]
8. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
11. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis.
Jin T; Bokarewa M; Amu S; Tarkowski A
Clin Exp Rheumatol; 2009; 27(3):491-4. PubMed ID: 19604443
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis.
McCarey D; Sturrock RD
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S124-6. PubMed ID: 19822058
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma.
Sarzi-Puttini P; Atzeni F; Shoenfeld Y; Ferraccioli G
Autoimmun Rev; 2005 Mar; 4(3):153-61. PubMed ID: 15823501
[TBL] [Abstract][Full Text] [Related]
15. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis.
Shen J; Shang Q; Tam LS
Transl Res; 2016 Jan; 167(1):138-51. PubMed ID: 26051628
[TBL] [Abstract][Full Text] [Related]
16. Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
Puttevils D; De Vusser P; Geusens P; Dens J
Acta Cardiol; 2014 Apr; 69(2):111-8. PubMed ID: 24783461
[TBL] [Abstract][Full Text] [Related]
17. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
[TBL] [Abstract][Full Text] [Related]
18. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Reiss AB; Silverman A; Khalfan M; Vernice NA; Kasselman LJ; Carsons SE; De Leon J
Curr Pharm Des; 2019; 25(9):969-986. PubMed ID: 31208307
[TBL] [Abstract][Full Text] [Related]
19. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
[TBL] [Abstract][Full Text] [Related]
20. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis.
Peters MJ; van Sijl AM; Voskuyl AE; Sattar N; Smulders YM; Nurmohamed MT
Curr Pharm Des; 2012; 18(11):1502-11. PubMed ID: 22364134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
